Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
|
|
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Deferred Prosecution Agreement",
"TEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ TEL AVIV, Israel & PARSIPPANY, N.J, August 21, 2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , has reached a deferred prosecution agreement with the U.S. Department of Justice to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will allow Teva to avoid mandatory exclusion from participation in U.S. federal health care programs, Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028. The Company has also agreed to donate $50 million worth of two generic products , to humanitarian organizations, and to divest one additional generic product to a third-party buyer. Teva admits in th..." |
|
| 08/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/02/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee",
"Opinion of Tulchinsky Marciano Cohen Levitski & Co. (Israeli law)",
"Opinion of Kirkland & Ellis LLP (New York law)",
"Opinion of Van Doorne N.V. (Dutch law)" |
|
| 03/03/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among the Issuers, the Company, Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE, Mizuho Securities Europe GMBH, Mizuho Securities USA LLC, MUFG Securities (Europe) N.V., MUFG Securities Americas Inc. and PNC Capital Markets LLC as representatives for the underwriters named in Schedule 1 annexed thereto",
"Proceeds to Repay Existing Debt" |
|
| 02/08/2023 |
8-K
| Quarterly results |
| 11/21/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 07/26/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 02/09/2022 |
8-K
| Quarterly results |
| 11/24/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/10/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Third Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent",
"Third Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee",
"Opinion of Tulchinsky Marciano Cohen Levitski & Co. (Israeli law)",
"Opinion of Kirkland & Ellis LLP (New York law)",
"Opinion of Van Doorne N.V. (Dutch law)" |
|
| 11/02/2021 |
8-K
| Other Events Interactive Data |
| 10/27/2021 |
8-K
| Quarterly results |
| 08/27/2021 |
8-K
| Quarterly results |
| 07/28/2021 |
8-K
| Quarterly results |
| 07/21/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/06/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/14/2021 |
8-K
| Quarterly results |
| 04/28/2021 |
8-K
| Quarterly results |
| 02/10/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 01/25/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
|
|
|